Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot lung cancer mutations faster

NCT ID NCT04912687

Diagnosis Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a simple blood test (liquid biopsy) can detect EGFR gene mutations in people with advanced non-small cell lung cancer. Researchers collected blood samples from 581 patients and compared the results with standard tissue testing. The goal was to see if adding the blood test helps find more patients who could benefit from targeted therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this approach could make it easier and faster to detect treatable genetic mutations in lung cancer, helping doctors choose the right treatment sooner.
What could go wrong
This is an observational study, not a treatment trial. It only tests a diagnostic method, so it won't directly improve outcomes. The blood test may miss some mutations found in tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

581 people

The number who actually took part.

Started

Jan 2022

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female patients aged ≥ 18 years at time of proposal study, 2. Histologically confirmed non-small cell lung carcinoma, 3. No previous treatment for NSCLC, 4. Indication to EGFR status determination following HAS recommendation, 5. Voluntary signed and dated written informed consent prior to any study specific procedure 6. Patients with a social security in compliance with the French Law. Exclusion Criteria: 1. Treatment for advanced NSCLC started before liquid biopsy sampling. 2. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumor Non-small cell lung cancer

Contacts and locations

Locations

  • CHRU Lille

    Lille, 59037, France

  • CHU Nice-Hopital de Cimiel

    Nice, 06000, France

  • CHU Poitiers

    Poitiers, 86021, France

  • CHU Strasbourg

    Strasbourg, 67091, France

  • CHU de Rennes - Hopital Pontchaillou

    Rennes, 35033, France

  • Hospices Civils de Lyon

    Lyon, 69002, France

  • Institut Bergonie

    Bordeaux, 33076, France

  • Institut Curie

    Paris, 75248, France

  • Institut de Cancérologie de l'Ouest - Site Paul Papin

    Angers, 49000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.